Clinical trial
Effect of Remimazolam Versus Propofol on Motor Evoked Potentials and Somatosensory Evoked Potentials During Spinal Tumor Surgery: A Randomized Controlled Trial
NCT07901504 is registered in ClinicalTrials.gov with Beijing Tsinghua Chang Gung Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started January 2027. Interventional study, Phase 4, 190 participants (estimated). Lead sponsor Beijing Tsinghua Chang Gung Hospital; China. Primary measure: MEP amplitude preservation ratio during the critical period of tumor manipulation. 3 linked papers.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Remimazolam Versus Propofol on Motor Evoked Potentials and Somatosensory Evoked Potentials During Spinal Tumor Surgery: A Randomized Controlled Trial
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- January 31, 2027
- Completion date
- February 29, 2028
- Enrollment
- 190 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Remimazolam-based total intravenous anesthesia | Experimental | Remimazolam |
Show registry wordingRemimazolam is administered for induction of anesthesia at 0.2-0.3 mg/kg intravenously and for maintenance by continuous infusion at 1-2 mg/kg/h, titrated to a bispectral index of 40-60. Depth of anesthesia, analgesia and neuromuscular blockade are standardized identically in both arms: sufentanil 0.3-0.5 micrograms/kg at induction, remifentanil 0.08-0.15 micrograms/kg/min for maintenance, and a single dose of rocuronium 0.6 mg/kg at induction with no intraoperative top-up. Core temperature is maintained at 36.0-37.5 degrees Celsius, mean arterial pressure within 10 percent of baseline and not below 80 mmHg, and heart rate between 50 and 100 beats per minute. | ||
| Propofol-based total intravenous anesthesia | Active comparator | Propofol |
Show registry wordingPropofol is administered for induction of anesthesia at 1.5-2.5 mg/kg intravenously and for maintenance by continuous infusion at 4-6 mg/kg/h, titrated to a bispectral index of 40-60. Depth of anesthesia, analgesia and neuromuscular blockade are standardized identically in both arms: sufentanil 0.3-0.5 micrograms/kg at induction, remifentanil 0.08-0.15 micrograms/kg/min for maintenance, and a single dose of rocuronium 0.6 mg/kg at induction with no intraoperative top-up. Core temperature is maintained at 36.0-37.5 degrees Celsius, mean arterial pressure within 10 percent of baseline and not below 80 mmHg, and heart rate between 50 and 100 beats per minute. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| MEP amplitude preservation ratio during the critical period of tumor manipulation | Intraoperative: from the baseline recording (after induction of anesthesia and before surgical incision) through the end of tumor manipulation |
Show registry wordingMean motor evoked potential (MEP) amplitude of the target muscles recorded during the critical period of tumor manipulation (time points T2 to T4), expressed as a percentage of the baseline (T0) amplitude. Baseline MEP amplitude is recorded after induction of anesthesia and before surgical incision, with a train-of-four ratio of at least 0.9. The primary analysis uses analysis of covariance with adjustment for baseline MEP amplitude, tumor type, tumor level, age and body mass index, under the intention-to-treat principle, with a per-protocol sensitivity analysis. The superiority margin is zero. | |
Papers
PubMed papers this trial cites; 3 papers, results papers first, then newest first.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
PROPOFOL
- US 4056635; expires November 1, 1996; assignee Imperial Chemical Industries Limited
-
Remimazolam
- US 9827251; expires January 23, 2034; assignee Paion UK Ltd.
- US 9561236; expires April 30, 2033; assignee Paion UK Ltd.
- US 10052334; expires November 7, 2031; assignee Paion UK Ltd.
- US 10195210; expires November 7, 2031; assignee Paion UK Ltd.
- US 10342800; expires November 7, 2031; assignee Paion UK Ltd.
- +6 more patents
Lead sponsor's other trials
Beijing Tsinghua Chang Gung Hospital, most recent start first.
+104 more trials See the organization page